ATE287391T1 - Stickstoff-senf-verbindungen und prodrugs dafür - Google Patents
Stickstoff-senf-verbindungen und prodrugs dafürInfo
- Publication number
- ATE287391T1 ATE287391T1 AT00918981T AT00918981T ATE287391T1 AT E287391 T1 ATE287391 T1 AT E287391T1 AT 00918981 T AT00918981 T AT 00918981T AT 00918981 T AT00918981 T AT 00918981T AT E287391 T1 ATE287391 T1 AT E287391T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- prodrugs
- nitrogen mustard
- group
- independently
- Prior art date
Links
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000651 prodrug Substances 0.000 title abstract 2
- 229940002612 prodrug Drugs 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9907414.8A GB9907414D0 (en) | 1999-03-31 | 1999-03-31 | Improvements relating to prodrugs |
| PCT/GB2000/001194 WO2000058271A1 (en) | 1999-03-31 | 2000-03-29 | Nitrogen mustard compounds and prodrugs therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE287391T1 true ATE287391T1 (de) | 2005-02-15 |
Family
ID=10850714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00918981T ATE287391T1 (de) | 1999-03-31 | 2000-03-29 | Stickstoff-senf-verbindungen und prodrugs dafür |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6852755B1 (de) |
| EP (1) | EP1165493B1 (de) |
| JP (1) | JP2002540186A (de) |
| AT (1) | ATE287391T1 (de) |
| AU (1) | AU3974600A (de) |
| CA (1) | CA2364622A1 (de) |
| DE (1) | DE60017551T2 (de) |
| GB (1) | GB9907414D0 (de) |
| NZ (1) | NZ513759A (de) |
| WO (1) | WO2000058271A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0220319D0 (en) * | 2002-09-02 | 2002-10-09 | Cancer Res Campaign Tech | Enzyme activated self-immolative nitrogen mustard drugs |
| EP2077991B1 (de) * | 2006-10-03 | 2014-02-26 | Techfields Biochem Co. Ltd | Positiv geladene, wasserlösliche prodrugs von losten und verwandten verbindungen mit sehr hohen hautpenetrationsraten |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
| GB8820850D0 (en) | 1988-09-05 | 1988-10-05 | Cancer Res Campaign Tech | Improvements relating to pro-drugs |
| EP0845537A1 (de) | 1989-08-18 | 1998-06-03 | Chiron Corporation | Rekombinante Retroviren, die einen Prodrug exprimieren, zur Behandlung von GVhD |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| GB8920011D0 (en) | 1989-09-05 | 1989-10-18 | Mann J | New route of synthesis for tertiary butyl esters |
| EP0572401B2 (de) | 1991-02-19 | 2007-11-07 | The Regents of the University of California | Viruspartikel mit veraendertem wirtspektrum |
| EP0615453B1 (de) | 1991-11-29 | 1997-05-14 | Chiron Viagene, Inc. | Immuntherapeutische vektorkonstrukte gegen krebs |
| GB9314960D0 (en) | 1992-07-23 | 1993-09-01 | Zeneca Ltd | Chemical compounds |
| GB9308957D0 (en) | 1993-04-30 | 1993-06-16 | Cancer Res Campaign Tech | Novel produgs |
| WO1995007994A2 (en) | 1993-09-15 | 1995-03-23 | Viagene, Inc. | Recombinant alphavirus vectors |
| CA2158936C (en) | 1993-11-18 | 2012-02-21 | Jack R. Barber | Compositions and methods for utilizing conditionally lethal genes |
| GB9415167D0 (en) | 1994-07-27 | 1994-09-14 | Springer Caroline J | Improvements relating to cancer therapy |
| GB9501052D0 (en) | 1995-01-19 | 1995-03-08 | Cancer Res Campaign Tech | Improvements relating to prodrugs |
| GB9514993D0 (en) | 1995-07-21 | 1995-09-20 | Pharmacia Spa | Site specific phenyl nitrogen mustards |
| GB9601640D0 (en) | 1996-01-26 | 1996-03-27 | Cancer Res Campaign Tech | Ligand directed enzyme prodrug therapy |
-
1999
- 1999-03-31 GB GBGB9907414.8A patent/GB9907414D0/en not_active Ceased
-
2000
- 2000-03-29 NZ NZ513759A patent/NZ513759A/xx not_active Application Discontinuation
- 2000-03-29 DE DE60017551T patent/DE60017551T2/de not_active Expired - Fee Related
- 2000-03-29 JP JP2000607975A patent/JP2002540186A/ja active Pending
- 2000-03-29 WO PCT/GB2000/001194 patent/WO2000058271A1/en not_active Ceased
- 2000-03-29 AT AT00918981T patent/ATE287391T1/de not_active IP Right Cessation
- 2000-03-29 AU AU39746/00A patent/AU3974600A/en not_active Abandoned
- 2000-03-29 CA CA002364622A patent/CA2364622A1/en not_active Abandoned
- 2000-03-29 EP EP00918981A patent/EP1165493B1/de not_active Expired - Lifetime
- 2000-03-29 US US09/937,714 patent/US6852755B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6852755B1 (en) | 2005-02-08 |
| JP2002540186A (ja) | 2002-11-26 |
| EP1165493A1 (de) | 2002-01-02 |
| EP1165493B1 (de) | 2005-01-19 |
| AU3974600A (en) | 2000-10-16 |
| GB9907414D0 (en) | 1999-05-26 |
| CA2364622A1 (en) | 2000-10-05 |
| DE60017551D1 (de) | 2005-02-24 |
| DE60017551T2 (de) | 2006-01-12 |
| NZ513759A (en) | 2001-09-28 |
| WO2000058271A1 (en) | 2000-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0415525A (pt) | derivados de imidazola e seu uso como agentes farmacêuticos | |
| IS6658A (is) | Ný efnasambönd | |
| IS6520A (is) | Ný efnasambönd | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| AR011116A1 (es) | Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene | |
| WO2004018475A3 (en) | Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents | |
| EP1819227A4 (de) | Pharmazeutische formulierungen von decitabin | |
| PL367682A1 (en) | Dolastatin 10 derivatives | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE233754T1 (de) | Diphenyl-piperidin derivate | |
| TR200101978T2 (tr) | 3,3-Biarilpiperidin ve 2,2-biarilmorfolin türevleri. | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| WO2004080960A3 (en) | Methods and compositions for the enzymatic synthesis of gangliosides | |
| SE0300456D0 (sv) | Novel compounds | |
| SE0003476D0 (sv) | Compounds | |
| SE0303280D0 (sv) | Novel compounds | |
| EA200600992A1 (ru) | Амиды тиазолидинона, амиды тиазолидинкарбоновой кислоты, способы их получения и их применение | |
| SE9902551D0 (sv) | Novel compounds | |
| MXPA02012426A (es) | Compuestos nuevos. | |
| ATE287391T1 (de) | Stickstoff-senf-verbindungen und prodrugs dafür | |
| YU19302A (sh) | 4-benzilaminohinolin konjugovan žučnom kiselinom i njegovi heteroanalozi, postupak za njihovu proizvodnju, lekovi koji sadrže ta jedinjenja i njihova primena | |
| SE0302755D0 (sv) | Novel compounds | |
| TW200504051A (en) | Novel acridine derivatives and their use as medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |